Clinician's Guide to Myasthenia Gravis

Jump to:

Autoimmune Care: Future Directions for Myasthenia Gravis and More

Written by Margaret Anne Rockwood | Last updated July 17, 2026
✅ Medically reviewed by Nizar Souayah, MD

 

Autoimmune disease therapy is entering a new era that moves beyond blunt, chronic immunosuppression and toward precise, long-lasting, disease-modifying interventions. In myasthenia gravis (MG), in particular, this shift is being exemplified by investigational FcRn inhibitors such as rozanolixizumab and efgartigimod, and complement C5 inhibitors such as zilucoplan, eculizumab, and ravulizumab.

The drug pipeline now spans:

  • next-generation monoclonal antibodies
  • engineered cell therapies
  • gene-editing and gene-replacement approaches
  • stem-cell-based immune reconstitution
  • antigen-specific tolerance platforms
  • novel biologic/small-molecule hybrids

Together, these strategies aim either to suppress pathological immune responses or to reprogram the immune system toward durable tolerance.

Monoclonal Antibodies and Next-Generation Biologics?

Monoclonal antibodies (mAbs) remain the workhorses of targeted immunotherapy. Early generations targeted cytokines (eg, TNFα, IL-6) or broad immune cell markers (eg, CD20), transforming disease courses in rheumatoid arthritis and inflammatory bowel disease. While these targets are not directly relevant to MG, they established the therapeutic paradigm that led to the MG-specific agents now in clinical use.

The next wave, however, is more nuanced and includes:

  • engineered antibodies with altered Fc function
  • bispecifics that bridge immune cells to defined targets
  • antibodies directed at trafficking or survival pathways for autoreactive B and plasma cells
  • neonatal Fc receptor (FcRn) blockers that accelerate the clearing of pathogenic IgG autoantibodies.
  • complement inhibitors that prevent the formation of the membrane attack complex (MAC) at the neuromuscular junction

These agents can selectively deplete pathogenic cell populations, interrupt antigen presentation, or block effector pathways, with improved safety compared with non-selective immunosuppression.

Cellular Therapies: CAR-T, CAAR-T, and Regulatory T cells

Adopting cell therapy lessons from oncology, researchers have applied chimeric antigen receptor (CAR) T-cell technology to autoimmunity. Two conceptual routes have emerged:

  1. CAR-T cells: engineered to deplete B cells broadly or plasma cells targeting a specific autoreactive B-cell clone. In early studies, CD19 CAR-T cell therapy has shown the ability to “reset” the B-cell system in refractory systemic lupus erythematosus. A recent, small Phase 1 trial found that anti-BCMA/CD19 CAR-T cell therapy may be effective in refractory generalized MG.
  2. CAAR-T cells (Chimeric Autoantibody Receptor): Using a similar mechanism of action, CAAR-T cells display an autoantigen to bind and kill only the autoreactive B cells.

In addition, CAR-Tregs (engineered regulatory T cells are designed to suppress pathogenic responses locally and restore immune tolerance. Early clinical and preclinical work indicates potent, sometimes prolonged, reductions in autoantibody titers after targeted cell infusion, offering a path toward drug-free remission for antibody-mediated diseases.

Safety challenges, such as cytokine release and off-target effects, and manufacturing/logistics remain active areas of study.

Gene Therapy and Replacement

Gene-based approaches include ex vivo gene replacement in hematopoietic stem cells (HSCs), in vivo viral vector delivery of tolerogenic factors, and precise genome editing (CRISPR/Cas systems) to reprogram immune cells.

In autoimmune disease care, gene therapy strategies may include delivery of tolerogenic cytokines through viral vectors, gene editing of autoreactive immune cells, or engineering hematopoietic stem cells to promote immune tolerance. Although myasthenia gravis is a polygenic autoimmune disease, gene-based approaches could enable long-term modulation of the immune responses responsible for pathogenic autoantibody production.

Recent advances in CRISPR-Cas9 gene editing have demonstrated clinical feasibility in other conditions (eg, transthyretin amyloidosis, sickle cell disease), providing a conceptual framework for immune-targeted applications in MG.

Stem Cell Transplantation and Immune Reconstitution

Autologous hematopoietic stem cell transplantation (AHSCT) provides an intense immune reset that clears the existing autoreactive repertoire and allows reconstitution under new tolerance dynamics. In several autoimmune diseases, including multiple sclerosis, AHSCT has produced durable remissions.

In MG, the evidence base remains limited to small case series, and AHSCT is considered investigational, reserved for selected patients with severe refractory disease when conventional and targeted therapies have failed.

The tradeoffs are procedural risk and transient immunodeficiency; thus, patient selection, conditioning regimens, and long-term follow-up are critical. Advances in conditioning strategies, toxicity reduction, and supportive care are steadily improving safety.

Antigen-Specific Tolerance and Small Modalities

Ultimately, antigen-specific tolerance, which retrains the immune system to ignore a defined self-antigen, is the optimal treatment goal.

Research into technologies includes tolerogenic nanoparticles carrying autoantigen peptides, DNA/RNA vaccines that induce regulatory responses, and ex vivo expanded antigen-specific Tregs. Because MG has clear autoantigen targets (ie, ChR, MuSK), it is theoretically well suited to antigen-specific approaches. The challenge is translating preclinical promise into clinically meaningful, durable tolerance in heterogeneous human immune systems.

On the Horizon

Over the next 5 to 10 years, a mixed strategy will likely emerge from improved monoclonal biologics and small molecules that provide safer, symptom-directed control; increasing use of B-cell and plasma-cell depleting cell therapies for refractory cases; incremental regulatory approvals for select cell and gene therapies; and increasingly rigorous late-phase trials testing antigen-specific tolerance platforms.

Cost, access, manufacturing capacity, and long-term safety data will determine which technologies become mainstream. For myasthenia gravis, specifically, the field will likely combine rapid antibody-lowering tools (already in use) with targeted cellular or gene approaches aimed at durable disease modification.

Sources

 

Our MG medical advisor

Dr. Nizar Souayah is an internationally renowned, triple board-certified neurologist with over 25 years of clinical and academic leadership.